Vet pharma firm wins US approval for antibiotic

INTERNATIONAL veterinary products company Dechra Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for a generic antibiotic.

The product is expected to be a first generic market entrant in a substantial antibiotic market and is the first registration the listed Northwich, Cheshire company has achieved through Putney’s development pipeline since it acquired the US-based business.

Dechra chief executive Ian Page said: “We are delighted to receive this approval which provides excellent growth opportunity for our US team and underpins our confidence in the strength of the recently acquired Putney business whilst further enhancing Dechra’s position in the US market.”

Earlier this week, Dechra reported underlying operating profit nat £52.9m (2015: £44.4m), on revenue of £247.6m (2015: £203.5m) for the year to the end of June. Pre-tax profits stood at £14.5m.